Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. - Wikidata - wikimedia - TriplyDB

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

http://www.wikidata.org/entity/Q50773376

about

Cancer-treatment-induced neurotoxicity--focus on newer treatments Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis.Lack of CD117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature.Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial Severe thrombocytopenia after trastuzumab retreatment: a case report.The use and impact of cancer medicines in routine clinical care: methods and observations in a cohort of elderly Australians Personalising pancreas cancer treatment: When tissue is the issue.Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent tr HER2 status and breast cancer therapy: recent advances.A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.Aromatase inhibitor strategies in metastatic breast cancer.Targeting HER2 in breast cancer: overview of long-term experience The epidermal growth factor receptor family in breast cancer.Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer.Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study HER-2 assessment in formalin-fixed paraffin-embedded breast cancer tissue by well-based reverse phase protein array Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group.Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer.Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.Docetaxel/trastuzumab combination therapy for the treatment of breast cancer.Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancers.Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.

P2860

Q26782604-7CF982F9-6288-4C86-8966-45C18A16F23C Q27025863-70AB346C-F0FA-4CBF-9B2C-81833D43BE4A Q28596492-6F1C6F80-E7F0-4280-BB16-8B4B5E37B9CD Q30544833-C093FCC1-943F-4990-AE89-BF2A12C72061 Q33246030-359BB0DD-5E77-4A28-89F0-896F6DE0A99F Q33279460-840DDCD6-F4EE-45B8-B196-FDA13A008219 Q33410733-CFAE993E-3A53-4380-9C98-6E66442E0CB1 Q33629327-189F9A85-11D6-41AA-BC13-AB7ED5AA0E1F Q33801384-674E349E-D5FE-4BFB-8622-0610715DB84C Q33973013-7FD5DC52-9392-4FEC-A905-B1A8E2A0781B Q34062418-97041CB3-F322-44ED-8585-4983533ED9E8 Q34077853-9D19578A-E520-412E-B8CD-E8F05D4E329D Q34250074-3BE4615A-BE78-4788-867A-2509F143DFC4 Q34272016-BCE27CAA-6CE3-47F0-AF42-F0845403489D Q34272044-C08E9F04-D443-4A38-AAF8-A13A016E2BB5 Q34363400-523B9F64-41A8-4D4B-8828-0BA4CC56E06B Q34417920-E2C57DBE-CA4B-4597-A751-99018BC53C76 Q34427231-92740F8B-EA22-488E-8AE7-860BB7DD3D0D Q34713799-D190D449-0681-4A2E-9899-15F0A60E1BBD Q34775370-310399B0-E922-4E16-8D37-93D3D14D4A24 Q34832259-F6CD6D67-5331-4F2D-A7B4-C577BA31B33A Q34964991-7844D1ED-21E0-40B4-9973-3B43C71269C4 Q35018233-18127F26-1E93-407F-9B4D-2CE5F46EDBC9 Q35079683-0E1F7939-4BDC-4E75-A3E8-4E6A1D65B126 Q35114038-2EEDD600-6249-4B34-B008-34176A5437FF Q35184966-F5E5DBB8-0859-4017-8CCA-C253BF963859 Q35527141-7BC3B9CE-75EF-4AAD-96C8-AF4F04C4B0C9 Q35540696-A457B101-1AFC-4822-BFDD-557ECF6403A8 Q35599781-5F89A6A2-C8EE-4394-81EA-1B0485AA4422 Q35871467-014019C5-B144-4085-B699-7ACA529276BF Q35880224-955EB28C-A7C8-4052-91FB-87FEAC276BE0 Q35896366-6B19C0A6-4940-4703-986B-8C0A47CE1CAE Q35909243-7B71FFBE-D803-4903-A0C9-D68B8FCCAB28 Q35927368-E2C277CA-207F-439C-8E84-670FDB92136D Q35989963-AFE406D7-D2A4-4B51-B11E-09DD21B3BFDB Q36107134-CAEEA621-6851-441E-BBA4-92B9A84FE71E Q36222001-602E064A-3FE9-4324-9EC1-B5C9BBBCC500 Q36252918-75611E90-EF43-424D-B24F-4501B9FD2537 Q36485216-7B4861E5-8183-4FBE-83D4-0EC955ADD171 Q36569759-78C1418D-A1FD-49BE-82AC-E767920420BB

P2860

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

http://www.wikidata.org/entity/Q50773376

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.

@en

Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.

@nl

type

label

Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.

@en

Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.

@nl

prefLabel

Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.

@en

Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.

@nl

P1433

Q50773376-6690A386-46CB-467B-8345-6A6094E9267E

P1476

Q50773376-8066BB62-A50D-460D-B0CD-3CAD138E969A

P2093

Q50773376-22AF48CD-94B5-441E-9D91-861ACD5B07C1

Q50773376-247A8D4B-C91E-49FB-92FC-67BE993C422C

Q50773376-3D483924-63E4-4E1C-8A18-2807FE81791A

Q50773376-9859DAF8-0248-41CA-ADD7-D6E7C8FA32F5

Q50773376-AF471CED-5005-4BA7-94E9-A8471BB31A92

Q50773376-B622C580-CEB6-4964-81EA-19BE324324F3

Q50773376-EABCDA51-A88C-4579-B293-80CD860A0E6A

Q50773376-F833853C-46B4-4939-BA28-AF68B1E61283

Q50773376-FAD775EE-6AD7-4CE0-84DB-201A9CEB6A8A

P304

Q50773376-C8775D08-DEE0-443F-B595-05B75E58E317

P31

Q50773376-4CE1C07F-F2B5-4F42-AE88-40F3951E97A3

P356

Q50773376-F8F935EF-AF34-4956-8A98-6ECF09123F1D

P407

Q50773376-3D2812ED-909C-4B32-8040-F120535997ED

P433

Q50773376-CB0D633C-2C26-469D-B923-69B21E9CE47C

P478

Q50773376-E6F54C6D-B02F-4D47-B9E2-6E03B1AED305

P577

Q50773376-C3907BB5-646F-4D5B-A30B-25A502C54F50

P698

Q50773376-8F4EC54D-A66F-424A-B514-06F53A284FF0

P356

JCO.2005.01.014

P1433

Journal of Clinical Oncology

P1476

Phase II study of efficacy, sa ...... stered on a 3-weekly schedule.

@en

P2093

Claire Barton

http://www.w3.org/2001/XMLSchema#string

José Baselga

http://www.w3.org/2001/XMLSchema#string

Michael Clemens

http://www.w3.org/2001/XMLSchema#string

Michael Green

http://www.w3.org/2001/XMLSchema#string

Noel-Jaime Castañeda-Soto

http://www.w3.org/2001/XMLSchema#string

Parviz Ghahramani

http://www.w3.org/2001/XMLSchema#string

Serafin Morales

http://www.w3.org/2001/XMLSchema#string

Vernon Harvey

http://www.w3.org/2001/XMLSchema#string

Xavier Carbonell

http://www.w3.org/2001/XMLSchema#string

P304

2162-2171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.01.014

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15800309

http://www.w3.org/2001/XMLSchema#string